To overcome these limitations, we have utilized immune stimulatory oncolytic Ad (RdB/IL12/DCN), which co-expresses IL-12 and DCN, to simultaneously degrade tumor ECM and reverse pancreatic tumor-induced immunosuppression by blocking TGF-β synthesis and activity (Oh et al. 2017; Heino et al. 1988; Kähäri et al. 1995; Mukhopadhyay et al. 2010). The gene discussed is TGFB1; the disease is neoplasm.